Abstract
PRDM13 (PR Domain containing 13) is a putative chromatin modifier and transcriptional regulator that functions downstream of the transcription factor PTF1A, which in turn controls GABAergic fate in the spinal cord and neuronal development in the hypothalamus. Here, we report a novel, recessive syndrome associated with PRDM13 mutation. Patients exhibited intellectual disability, ataxia with cerebellar hypoplasia, scoliosis and delayed puberty with congenital hypogonadotropic hypogonadism (CHH). Expression studies revealed Prdm13/PRDM13 transcripts in the developing hypothalamus and cerebellum in mouse and human. We investigated the development of hypothalamic neurons and the cerebellum in mice homozygous for a Prdm13 mutant allele.
A significant reduction in the number of Kisspeptin (Kiss1) neurons in the hypothalamus and PAX2+ progenitors emerging from the cerebellar ventricular zone were observed. The latter was accompanied by ectopic expression of the glutamatergic lineage marker TLX3. Phenotypically, mice lacking PRDM13 displayed cerebellar hypoplasia, normal gonadal structure, but delayed pubertal onset. Together, these findings identify PRDM13 as a critical regulator of GABAergic cell fate in the cerebellum and of kisspeptin neuron development in the hypothalamus, providing a mechanistic explanation for the co-occurrence of CHH and cerebellar hypoplasia in this syndrome. To our knowledge, this is the first evidence linking disrupted PRDM13-mediated regulation of Kiss1 neurons to CHH in humans.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
RO was supported by a short-term fellowship from EMBO (number 7950) to visit the Basson lab. DEW was supported by an Integrated Training Fellowship from the Wellcome Trust (WT096385MA) and short-term fellowship support from the Royal Veterinary College and Kings College London and a Starter Grant for Clinical Lecturers (SGL023_111). MTD receives funding from the Great Ormond Street Hospital (GOSH) Childrens Charity and the Medical Research Foundation UK (grant# 535963). Research at GOSH benefits from funding received from the NIHR Biomedical Research Centre. AC was funded by the Italian Ministry of Health (GR-2016-02362389). TF was funded by Grant-in-Aid for Scientific Research (18H02593) from the Japan Society for the Promotion of Science and The Takeda Science Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institute of Child Health/Great Ormond Street Hospital for Children Joint Research Ethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first authors
Data Availability
Requests for raw data and materials should be made to the corresponding authors. No large data sets form part of the manuscript.
